Research

Macro partitioning

GLP-1 receptor agonist pharmacotherapy in older adults causes significant loss of lean skeletal muscle mass (approx. 26-40% of total weight lost), which independently predicts adverse outcomes including mortality, functional decline, and frailty.

If you are an older adult using GLP-1 medications, do not focus solely on the number on the scale. The medication causes you to lose muscle along with fat, which can lead to frailty and higher mortality. You must actively counteract this by combining your medication with resistance exercise and adequate protein intake to preserve your muscle mass.

ModerateSupportsMEDIUM confidence
Pooled data for approximately 40%–60% of total weight lost with GLP-1 therapy from STEP 1 and SURMOUNT-1 indicate that in participants aged ≥65, lean mass accounted for approximately 40% and 26% of total weight lost, respectively... weight loss in older adults significantly decreases thigh muscle area, independently predicting greater mortality (Santanasto et al., 2017).
Kieran F. Reid et al. · Frontiers in Aging · 2025

Why this rating

The paper is a perspective/review citing retrospective subgroup analyses and epidemiological data; it highlights evidence gaps rather than presenting new primary RCTs.

Source

Moving beyond the scale: musculoskeletal risks, evidence gaps and emerging combination strategies to optimize the quality of weight loss pharmacotherapy in older adults

Kieran F. Reid et al. · Frontiers in Aging · 2025

DOI 10.3389/fragi.2025.1640030

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →